Colorectal cancer (CRC) is the fourth most diagnosed cancer and second leading cause of cancer death in the U.S. with 95,270 and 39,220 new cases of colon and rectal cancer projected in 2016, respectively (NCCN, 2017). Additionally, 49,190 people are expected to die from CRC. While EGFR is overexpressed in However, EGFR, the target of these drugs, which is overexpressed in approximately 80% of colorectal carcinomas, failed to predict a therapeutic response to anti-EGFR therapies. KRAS and NRAS genes are the frequently mutated genes downstream of the EGFR signaling pathway, and considered candidate biomarkers for anti-EGFR therapy. These biomarkers have been identified to harbor insensitivity to anti-EGFR therapies with cetuximab and panitumumab.